Effects of 2 different anti-tumor necrosis factor-alpha agents in a primate model of subcutaneous abscess formation.

Tumor necrosis factor (TNF)-alpha exerts both physiologic and pathologic effects in response to infection, conferring the benefit of host defense against infection at the risk of eliciting severe pathology if the response is excessive or inappropriate. In the present study, the effects of an anti-TNF-alpha monoclonal antibody (MAb) and a TNF-alpha receptor construct (p75-Fc) were compared with that of saline in a primate model of subcutaneous abscess induced with Staphylococcus aureus. Intravenous administration of anti-TNF-alpha MAb delayed the onset and reduced the incidence and the severity of abscess formation in response to inoculation with S. aureus at concentrations of 10(9) and 10(10) cfu/mL, compared with administration of saline. In contrast, no improvement in abscess formation was observed in animals treated with p75-Fc. These results supply initial evidence that anti-TNF-alpha MAb, unlike p75-Fc, provides a beneficial effect in this abscess model.

[1]  C. Dinarello,et al.  Tumor necrosis factor (TNF)-alpha-induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors. , 2000, The Journal of infectious diseases.

[2]  J. Pober,et al.  Recent advances in the molecular basis of TNF signal transduction. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[3]  F. Brennan,et al.  Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases. , 1998, Transplantation proceedings.

[4]  S. Streat,et al.  Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis--a randomized, clinical trial. , 1998, Critical care medicine.

[5]  M. Su,et al.  Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. , 1998, The Journal of clinical investigation.

[6]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[7]  P. Vassalli,et al.  Evidence for a protective role of tumor necrosis factor in the acute phase of Trypanosoma cruzi infection in mice , 1997, Infection and immunity.

[8]  K. Matsushima,et al.  Interleukin 8 as a novel target for intervention therapy in acute inflammatory diseases. , 1996, Molecular medicine today.

[9]  S. Sharar,et al.  L-selectin (CD62L) blockade does not impair peritoneal neutrophil emigration or subcutaneous host defense to bacteria in rabbits. , 1996, Journal of immunology.

[10]  R. Geha,et al.  Affinity maturation without germinal centres in lymphotoxin-α-deficient mice , 1996, Nature.

[11]  B. Beutler,et al.  The tumor necrosis factor ligand and receptor families. , 1996, The New England journal of medicine.

[12]  S. Opal,et al.  Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. , 1996, The New England journal of medicine.

[13]  J. Cohen,et al.  Bacterial superantigen-induced human lymphocyte responses are nitric oxide dependent and mediated by IL-12 and IFN-gamma. , 1996, Journal of immunology.

[14]  N. Voitenok,et al.  Homologous ELISA for detection of oligomeric human TNF: properties of the assay. , 1995, Journal of immunological methods.

[15]  L. Picker,et al.  Bacterial superantigens induce T cell expression of the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen, via stimulation of interleukin 12 production , 1995, The Journal of experimental medicine.

[16]  G. Trinchieri,et al.  The role of interleukin 12 in the immune response, disease and therapy. , 1994, Immunology today.

[17]  L. Picker.  Control of lymphocyte homing. , 1994, Current opinion in immunology.

[18]  M. O’Donnell,et al.  In vivo augmentation of IFN-gamma with a rIL-12 human/mouse chimera: pleiotropic effects against infectious agents in mice and rats. , 1994, Cytokine.

[19]  S. Sharar,et al.  P-selectin blockade does not impair leukocyte host defense against bacterial peritonitis and soft tissue infection in rabbits. , 1993, Journal of immunology.

[20]  B. Scallon,et al.  Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. , 1993, Molecular immunology.

[21]  B. Beutler,et al.  Tumor necrosis factor in the pathogenesis of infectious diseases , 1993, Critical care medicine.

[22]  L. Tartaglia,et al.  Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. , 1993, The Journal of biological chemistry.

[23]  C A Smith,et al.  Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. , 1993, Journal of immunology.

[24]  D. Stevens,et al.  Superantigens associated with staphylococcal and streptococcal toxic shock syndrome are potent inducers of tumor necrosis factor-beta synthesis. , 1993, The Journal of infectious diseases.

[25]  G. Bancroft,et al.  Cytokine enhancement of complement‐dependent phagocytosis by macrophages: synergy of tumor necrosis factor‐α and granulocyte‐macrophage colony‐stimulating factor for phagocytosis of Cryptococcus neoformans , 1992, European journal of immunology.

[26]  E. Berg,et al.  The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for the vascular lectin endothelial cell-leukocyte adhesion molecule 1 , 1991, The Journal of experimental medicine.

[27]  K. Bayston,et al.  Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-alpha in experimental gram-negative shock. , 1990, The Journal of infectious diseases.

[28]  U. Andersson,et al.  Production of TNF-alpha and TNF-beta by staphylococcal enterotoxin A activated human T cells. , 1990, Journal of immunology.

[29]  S. Opal,et al.  Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa. , 1990, The Journal of infectious diseases.

[30]  A. Chang,et al.  Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). , 1990, Circulatory shock.

[31]  V. Kindler,et al.  The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection , 1989, Cell.

[32]  Kevin J. Tracey,et al.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.

[33]  B. Beutler,et al.  The endogenous mediator of endotoxic shock. , 1987, Clinical research.

[34]  T. Espevik,et al.  A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. , 1986, Journal of immunological methods.

[35]  B. Beutler,et al.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. , 1985, Science.

[36]  Bharat B. Aggarwal,et al.  Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin , 1984, Nature.

[37]  M. Feldmann,et al.  Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? , 2001, Annual review of immunology.

[38]  N. Ruddle.  Lymphoid neo-organogenesis: lymphotoxin's role in inflammation and development. , 1999, Immunologic research.

[39]  C. Ware,et al.  LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. , 1998, Immunity.

[40]  B. Castner,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. , 1997, Nature.

[41]  R. Geha,et al.  Affinity maturation without germinal centres in lymphotoxin-alpha-deficient mice. , 1996, Nature.

[42]  C. Ware,et al.  The ligands and receptors of the lymphotoxin system. , 1995, Current topics in microbiology and immunology.

[43]  L. Picker,et al.  Physiological and molecular mechanisms of lymphocyte homing. , 1992, Annual review of immunology.